SABS Archives - BioTuesdays

Executive Moves

SAB Biotherapeutics names Michael G. King Jr. as CFO

SAB Biotherapeutics (NASDAQ:SABS) appointed Michael G. King Jr. as CFO, effective Oct 30. Mr. King replaces Russell Beyer, who is expected to step down on Nov. 15 and remain a senior advisor with the company for the...

October 25, 2023

Developments

SAB presents positive Phase 1, 2a data in influenza

SAB Biotherapeutics (NASDAQ:SABS) presented positive safety and efficacy data from Phase 1 and 2a clinical trials of its influenza immunotherapy, SAB-176, at the AVG conference, which is hosted by the International...

May 4, 2023

Developments

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics (NASDAQ:SABS) reported positive top-line results from the Phase 3 National Institutes of Health’s ACTIV-2 clinical trial that assessed SAB-185 in non-hospitalized people with COVID-19 who were at...

April 26, 2023

Developments

SAB Biotherapeutics nabs FDA breakthrough status for Influenza immunotherapy

The FDA granted breakthrough therapy designation for SAB Biotherapeutics’ (NASDAQ:SABS) SAB-176, an investigational therapeutic, for post-exposure prophylaxis for Type A and Type B influenza illness in high-risk...

April 18, 2023

Developments

SAB Biotherapeutics presents new influenza and COVID-19 data

SAB Biotherapeutics (NASDAQ:SABS) presented new data at the Options for Control of Influenza conference in Belfast, showing its fully-human polyclonal antibody platform maintains its efficacy against multiple variants...

September 28, 2022

Feature

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics (NASDAQ:SABS) is developing its novel DiversitAb platform to produce a new class of specifically targeted, high-potency, fully-human polyclonal antibodies, without the need for human donors.

September 13, 2022

Developments

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

SAB Biotherapeutics (NASDAQ:SABS) will be discontinuing its work with the U.S. Department of Defense (DoD) under a prototype research and development agreement. The agreement, which was awarded in the summer of 2019...

August 10, 2022

Tag - SABS

SAB Biotherapeutics names Michael G. King Jr. as CFO

SAB presents positive Phase 1, 2a data in influenza

SAB posts positive Phase 3 results in high-risk COVID-19 patients

SAB Biotherapeutics nabs FDA breakthrough status for Influenza immunotherapy

SAB Biotherapeutics presents new influenza and COVID-19 data

SAB Biotherapeutics advancing new class of immunotherapeutic antibodies

SAB Biotherapeutics expanding pipeline for C. diff as DoD contract winds down

General

More